RENBP and neoplasm: Still, these expanded cell products could mediate tumor cell killing, which is of high relevance, as this patient group is less likely to respond to ICI therapy, and suggests that Ag-scaffold–mediated expansion of T-Ag–specific T cells could be a beneficial treatment strategy for the nonresponding patient group, potentially in combination with an HLA upregulation agent to limit this immune evasion.